Want to see LENZ full AI Analyst Report?
LENZ Stock Chart & Stats
$4.81
$0.43(8.51%)
At close: 4:00 PM EDT
$4.81
$0.43(8.51%)
Day’s Range― - ―
52-Week Range$4.54 - $50.40
Previous CloseN/A
Volume1.43M
Average Volume (3M)765.75K
Market Cap
$182.24M
Enterprise Value-$41.23
Total Cash (Recent Filing)$220.00M
Total Debt (Recent Filing)$122.00K
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Nov 11, 2026EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.09
Shares Outstanding31,420,343
10 Day Avg. Volume605,752
30 Day Avg. Volume765,747
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)1.62
Price to Sales (P/S)24.15
P/FCF Ratio-6.59
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$24.40Price Target Upside407.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.49
Revenue Forecast (FY)$18.98M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And High Gross MarginRapid revenue expansion and high direct-product margins indicate improving commercial economics. If sales scale as expected, the margin profile could provide operating leverage and support a viable long-term ophthalmic franchise.
Early Patient PersistenceRepeat purchasing is an important indicator for a prescription product because it supports recurring demand rather than one-time trial. Sustained refill behavior could improve customer economics and make future commercial spending more productive.
Global Expansion And Licensing PlatformA broad partner and regulatory footprint gives LENZ multiple routes to international commercialization without funding every market independently. Milestone and licensing activity can diversify revenue and extend VIZZ's addressable market.
Bears Say
Large Operating LossesThe scale of operating losses remains disproportionate to current revenue, showing that the business has not yet reached commercial operating leverage. Continued expense intensity could delay breakeven and require additional financing.
Substantial Cash Burn And Funding DependencePersistent negative cash generation means LENZ must fund development and commercialization largely from its cash balance or external capital. Even with low debt, prolonged burn can reduce flexibility and create dilution or refinancing risk.
Product Revenue Still Small Versus SpendingCommercial traction remains early, with product sales far below the cost base and limited retail visibility. This constrains confidence in broad-based adoption and leaves the company dependent on proving that newer channels can generate durable demand.
LENZ Therapeutics News
LENZ FAQ
What was LENZ Therapeutics’s price range in the past 12 months?
LENZ Therapeutics lowest stock price was $4.54 and its highest was $50.40 in the past 12 months.
What is LENZ Therapeutics’s market cap?
LENZ Therapeutics’s market cap is $182.24M.
When is LENZ Therapeutics’s upcoming earnings report date?
LENZ Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 67 days.
How were LENZ Therapeutics’s earnings last quarter?
LENZ Therapeutics released its earnings results on Aug 11, 2026. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.05 by $0.03.
Is LENZ Therapeutics overvalued?
According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued.
Does LENZ Therapeutics pay dividends?
LENZ Therapeutics pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here
What is LENZ Therapeutics’s EPS estimate?
LENZ Therapeutics’s EPS estimate is -0.93.
How many shares outstanding does LENZ Therapeutics have?
LENZ Therapeutics has 31,420,343 shares outstanding.
What happened to LENZ Therapeutics’s price movement after its last earnings report?
LENZ Therapeutics reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.05. Following the earnings report the stock price went down -3.263%.
Which hedge fund is a major shareholder of LENZ Therapeutics?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.40 (407.28% Upside)
$24.40 (407.28% Upside)
Blogger Sentiment
Neutral
LENZ Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
LENZ Therapeutics
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
LENZ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of encouraging commercial signals and meaningful operational/financial challenges. Positive indicators include strong early patient persistence in the e‑pharmacy channel (60%+ repeat purchasers and mature cohorts trending to ~5 packs/year), a notable >45% month‑over‑month script lift in July after launching telehealth and national TV, expanding global partnerships and multiple regulatory submissions, and a strong cash balance (~$220M) with an expected high direct product gross margin (~90%). Offsetting these positives are modest product revenue ($1.7M) relative to high operating expenses (Q2 net loss $31.9M; SG&A $39.4M), limited retail channel pickup and visibility, and the caveat that July’s improvement is an early one‑month signal that may not yet represent a durable trend. Management emphasized discipline in capital allocation and a data‑driven reallocation of commercial spend to activities that demonstrably drive durable patient growth.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$24.40
▲(407.28% Upside)
Technical Analysis
Ownership Overview
15.21% Insiders
15.84% Mutual Funds
50.49% Other Institutional Investors
9.49% Public Companies and
Individual Investors